Hi All, Check out Dr Ben Turners talk featured on*, he's refreshingly honest about how hard it is to spot the transition from RRMS to SPMS; he talks about active MRI lesions too, which some PPMSers can get (see below). PRMS is about to be redefined out of existence, but that probably means they can treat it like RRMS or not treat it at all- active MRI lesions seem the be the criterion for treatment. We all have our off days ... *Multiple Sclerosis Research: MS Day: Progression 18 Sep 2014 MS Day: Progression. Today Ben Turner talks about Progression Dr Ben Turner: Q &. A How can a neurologist see a transition from RRMS to SPMS in a patient if they don't give you MRI scan? I cannot predict SPMS from the ... http://multiple-sclerosis-research.blogspot.com/ Pasted from <http://multiple-sclerosis-research.blogspot.co.uk/#uds-search-results> Multiple Sclerosis Research: What DMT would you ... 14 May 2011 The latter study is based on the observations from a subgroup analysis of the Rituximab PPMS trial that showed younger patients (<51 years) and those with active MRI scans (Gd-enhancing lesions) responded to treatment; ... http://multiple-sclerosis-research.blogspot.com/ Multiple Sclerosis Research: Clinical Practice in the USA 11 May 2012 Current US treatment patterns emphasize MRI in MS diagnosis and subsequent treatment decisions, treatment of early disease, aggressive initial treatment of highly active MS, and close MSer monitoring. ... For PPMS, responses supported diagnosis using spinal MRI (100%) and lumbar puncture (75%) and treatment initiation in patients with brain gadolinium-enhancing lesions with or without spinal cord lesions (85%); however, there was no consensus on treatment ... http://multiple-sclerosis-research.blogspot.com/ Multiple Sclerosis Research: PPMS and RRMS are the ... 10 May 2014 "The MRI study below demonstrates that lesions on MRI in MSers with relapse-onset or primary progressive MS are identical. They interpret that these clinical sub-types as being the same disease. This supports all the other ... http://multiple-sclerosis-research.blogspot.com/ Clinic Speak: off-label and private prescribing in PPMS 19 May 2014 What happens if someone with PPMS who is young and has active inflammation on MRI and wants to pay for his or her own treatment? Do I say no ... Subgroup analysis showed time to CDP was delayed in rituximab-treated patients aged <51 years (hazard ratio [HR] = 0.52; p = 0.010), those with gadolinium-enhancing lesions (HR = 0.41; p = 0.007), and those aged <51 years with gadolinium-enhancing lesions (HR = 0.33; p = 0.009) compared with placebo. Adverse ... http://multiple-sclerosis-research.blogspot.com/ Pasted from <http://multiple-sclerosis-research.blogspot.co.uk/#uds-search-results>